A case of anti-HMGCR myopathy in a patient with breast cancer and anti-Th/To antibodies

Statins competitively inhibit the activity of HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), which is a key enzyme in cholesterol synthesis. These are effective drugs for the management of cardiovascular disease and are generally well tolerated but several side effects have been reported....

Descripción completa

Detalles Bibliográficos
Autores principales: Chérif, Mohammad Yassine, Raftakis, Ioannis, Weynand, Marjolaine, Dragan, Elena, Nagant, Carole, Lecomte, Sophie, Badot, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530299/
https://www.ncbi.nlm.nih.gov/pubmed/37771688
http://dx.doi.org/10.1093/omcr/omad097
Descripción
Sumario:Statins competitively inhibit the activity of HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), which is a key enzyme in cholesterol synthesis. These are effective drugs for the management of cardiovascular disease and are generally well tolerated but several side effects have been reported. Muscular adverse symptoms are various and, rarely, statin exposure may lead to authentic immune-mediated necrotizing myopathy (IMNM), namely anti-HMGCR myopathy. However, cases of IMNM associated with cancer have been described. We discuss herein a case of IMNM in a patient with breast cancer previously exposed to statins and with the presence of anti-Th/To antibodies without clinical correlation.

Ejemplares similares